SALARIUS PHARMACEUTICALS INC (SLRX) Stock Price, Quote, News and Overview
NASDAQ:SLRX - Nasdaq - US79400X4043 - Common Stock - Currency: USD
SLRX Quote, Performance and Key Statistics
NASDAQ:SLRX (2/20/2025, 8:00:01 PM)
1.35
-0.07 (-4.93%)
The current stock price of SLRX is 1.35 USD. In the past month the price decreased by -49.63%. In the past year, price decreased by -70.75%.
SLRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.85 | 354.98B | ||
| AMGN | AMGEN INC | 15.03 | 159.99B | ||
| GILD | GILEAD SCIENCES INC | 23.87 | 137.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1656.31 | 123.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.25 | 76.09B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.37B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.06B | ||
| NTRA | NATERA INC | N/A | 22.20B | ||
| BIIB | BIOGEN INC | 8.32 | 19.98B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.01B |
Related stock screener links
About SLRX
Company Profile
Salarius Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The firm is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening and further optimization with structure-activity relationship studies.
Company Info
SALARIUS PHARMACEUTICALS INC
2450 Holcombe Blvd Ste J-608
Houston TEXAS 77021 US
CEO: David J. Arthur
Employees: 2
Company Website: https://salariuspharma.com/
Investor Relations: http://ir.flex-pharma.com/phoenix.zhtml?c=253862&p=irol-irhome
Phone: 13467720346
SALARIUS PHARMACEUTICALS INC / SLRX FAQ
What is the stock price of SALARIUS PHARMACEUTICALS INC today?
The current stock price of SLRX is 1.35 USD. The price decreased by -4.93% in the last trading session.
What is the ticker symbol for SALARIUS PHARMACEUTICALS INC stock?
The exchange symbol of SALARIUS PHARMACEUTICALS INC is SLRX and it is listed on the Nasdaq exchange.
On which exchange is SLRX stock listed?
SLRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SALARIUS PHARMACEUTICALS INC stock?
6 analysts have analysed SLRX and the average price target is 26.52 USD. This implies a price increase of 1864.44% is expected in the next year compared to the current price of 1.35. Check the SALARIUS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SALARIUS PHARMACEUTICALS INC worth?
SALARIUS PHARMACEUTICALS INC (SLRX) has a market capitalization of 2.13M USD. This makes SLRX a Nano Cap stock.
How many employees does SALARIUS PHARMACEUTICALS INC have?
SALARIUS PHARMACEUTICALS INC (SLRX) currently has 2 employees.
What are the support and resistance levels for SALARIUS PHARMACEUTICALS INC (SLRX) stock?
SALARIUS PHARMACEUTICALS INC (SLRX) has a resistance level at 2.38. Check the full technical report for a detailed analysis of SLRX support and resistance levels.
Should I buy SALARIUS PHARMACEUTICALS INC (SLRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SLRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SLRX, evaluating the profitability, health, valuation and growth aspects
- SALARIUS PHARMACEUTICALS INC (SLRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SALARIUS PHARMACEUTICALS INC (SLRX) Sales and EPS estimates to see what analysts future expectations are.
- SALARIUS PHARMACEUTICALS INC (SLRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SALARIUS PHARMACEUTICALS INC (SLRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- SALARIUS PHARMACEUTICALS INC (SLRX) Stock Chart to make your own analysis
- SALARIUS PHARMACEUTICALS INC (SLRX) Latest news and press-releases to stay up to date.
Does SALARIUS PHARMACEUTICALS INC (SLRX) stock pay dividends?
SLRX does not pay a dividend.
When does SALARIUS PHARMACEUTICALS INC (SLRX) report earnings?
SALARIUS PHARMACEUTICALS INC (SLRX) will report earnings on 2025-03-20, after the market close.
What is the Price/Earnings (PE) ratio of SALARIUS PHARMACEUTICALS INC (SLRX)?
SALARIUS PHARMACEUTICALS INC (SLRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.19).
What is the Short Interest ratio of SALARIUS PHARMACEUTICALS INC (SLRX) stock?
The outstanding short interest for SALARIUS PHARMACEUTICALS INC (SLRX) is 1.25% of its float. Check the ownership tab for more information on the SLRX short interest.
SLRX Technical Analysis
SLRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SLRX. Both the profitability and financial health of SLRX have multiple concerns.
SLRX Financial Highlights
Over the last trailing twelve months SLRX reported a non-GAAP Earnings per Share(EPS) of -8.19. The EPS decreased by -14.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -129.4% | ||
| ROE | -170.75% | ||
| Debt/Equity | 0.11 |
SLRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to SLRX. The Buy consensus is the average rating of analysts ratings from 6 analysts.